FY2025 · ended Dec 31, 2025 · Revenue $719.89M, -1.7% YoY · Filed Feb 26, 2026
Amphastar Pharmaceuticals, Inc. (AMPH) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $719.9 million and net income of $98.1 million. Free cash flow was $121.2 million. As of Jun 30, 2026 it held $290.1 million in cash and investments and $637.0 million in total debt.
Revenue (TTM)
$730.02M
+1.0% vs year-ago TTM
Net income (TTM)
$78.55M
-41.7% vs year-ago TTM
Operating cash flow (TTM)
$184.61M
+15.6% vs year-ago TTM
Free cash flow (TTM)
$152.89M
+36.3% vs year-ago TTM
EPS (TTM)
$1.69
-36.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
45.37M
-4.8% vs prior year
Net cash
$-346.84M
as of Jun 30, 2026
Operating margin
15.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMPH (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Rancho Cucamonga, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1297184
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M |
| Net income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M |
| Diluted EPS | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 |
| Operating cash flow | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M |
| Free cash flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M |
| Total assets | $1.6B | $1.6B | $1.5B | $742.0M | $671.5M |
| Total liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M |
| Stockholders' equity | $788.8M | $732.3M | $639.4M | $528.7M | $445.5M |
| Cash and investments | $282.8M | $232.6M | $271.5M | $175.8M | $136.7M |
| Total debt | $665.6M | $662.6M | $637.4M | $104.1M | $106.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 13, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Other events
|
Jul 8, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | Jun 1, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 954 Amphastar Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.